Abstract: Disclosed is an imidazole compound, in particular, the compound as shown in formula (I) and a pharmaceutically acceptable salt or tautomer thereof are disclosed.
Abstract: A compound exerts a strong analgesic effect against pain, in particular, neuropathic pain and/or fibromyalgia syndrome. A cyclic amine derivative represented by general formula or a pharmacologically acceptable salt thereof A method of treating neuropathic pain includes administering a therapeutically effective amount of the cyclic amine derivative to a mammal. A method of treating fibromyalgia syndrome includes administering a therapeutically effective amount of the cyclic amine derivative to a mammal.
Abstract: Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. In advanced lesions, senescent cells promote features of plaque instability, including elastic fiber degradation and fibrous cap thinning, by heightening metalloprotease production. This invention provides methods and materials for treating arthritis by removing senescent cells in or around atherosclerotic plaques, thereby stabilizing the plaques, inhibiting rupture of the plaques and pathological sequelae that manifest as coronary artery disease.
Type:
Application
Filed:
October 24, 2017
Publication date:
April 19, 2018
Inventors:
Bennett G. Childs, Jan M.A. van Deursen
Abstract: (3S)-Tetrahydrofuran-3-yl(4S)-4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]-pyridine-5-carboxylate, and salts thereof for use in the treatment of pain.
Type:
Application
Filed:
April 22, 2016
Publication date:
April 19, 2018
Applicant:
PROXIMAGEN LIMITED
Inventors:
Isabel GONZALEZ, Martyn PRITCHARD, Peter RICHARDSON
Abstract: A pharmaceutical compositions comprising: (a) a carbapenem antibacterial agent selected from imipenem, meropenem, ertapenem, doripenem or a pharmaceutically acceptable derivative thereof, and (b) a compound of Formula (I), or a stereoisomer or a pharmaceutical acceptable derivative thereof, are disclosed.
Abstract: A bowel cleansing composition includes as a first cleansing ingredient, a specific sugar alcohol such as xylitol, sorbitol, etc., as a second cleansing ingredient glycerol, erythritol, threitol, arabitol, ribitol, mannitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol, and polyglycitol, as a second cleansing ingredient ascorbic acid or a mixture of ascorbic acid and a salt of ascorbic acid, as a third cleansing ingredient picosulfate, and an aqueous solvent, wherein the concentration of the first cleansing ingredient is 10 g/L to 500 g/L based on the total composition, the concentration of the second cleansing ingredient is 15 g/L to 500 g/L based on the total composition, the concentration of the third cleansing ingredient is 1 mg/L to 100 mg/L based on the total composition, and the volume of the aqueous solvent is 0.1 L to 1.0 L.
Type:
Application
Filed:
December 15, 2017
Publication date:
April 19, 2018
Inventors:
Yoon Sik Kang, Chung Yoon Shin, Hyun Suk Kang, Hyun Yee Kang
Abstract: The invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.
Abstract: The present invention relates to a nail lacquer composition containing at least one antifungal agent as a pharmacologically active ingredient. The present invention has an excellent penetrating effect of a drug in skin areas where the drug is applied because of needing treatment and, specifically, in fingernails by containing a polymer material which forms a specific film, and a penetration enhance, is convenient for management after locally applying the drug to a treatment site, and has excellent storage stability of the drug.
Type:
Application
Filed:
March 9, 2016
Publication date:
April 19, 2018
Inventors:
Nam-hyang KIM, Yong-baik CHO, Sang-young JEONG, Byoung-chan BAE, Jae-seong LEE, Ji-won LEE, Hong-koo CHO
Abstract: The present invention provides, inter alia, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.
Type:
Application
Filed:
October 30, 2017
Publication date:
April 19, 2018
Inventors:
Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
Abstract: The present invention relates to novel biologically active glutarimide derivatives of general formula (I) or a pharmaceutically acceptable salt thereof, their use as a therapeutic agent for the treatment of eosinophilic diseases, preferably of allergic nature, in particular bronchial asthma, allergic rhinitis, polypous rhinosinusopathies, eosinophilic colitis, eosinophilic syndrome, allergic conjunctivitis, atopic dermatitis, Churg-Strauss syndrome, anaphylactic shock, Quincke's edema, eosinophilic vasculitis, eosinophilic esophagitis, eosinophilic gastroenteritis, or fibroses.
Type:
Application
Filed:
December 18, 2017
Publication date:
April 19, 2018
Inventors:
Vladimir Evgenievich NEBOLSIN, Tatyana Alexandrovna KROMOVA, Anastasia Vladimirovna RYDLOVSKAYA, Alexander Grigorievich CHUCHALIN
Abstract: The present invention relates to pharmaceutical composition(s) containing active ingredient and inactive ingredients without preservative(s). The pharmaceutical composition contains an active ingredient for treating allergic conjunctivitis, spring catarrh, pollinosis, and the like. The pharmaceutical composition is packaged in unit-of-use or multi-dose containers. The claimed composition reduces side effects associated with multiple administration of eye-drops containing preservatives.
Abstract: Described herein are methods for treating breast cancer and for providing a prognosis for metastatic-free survival of breast cancer patients. Aspects relate to treating a patient determined to be at high risk for developing or having metastatic breast cancer comprising administering adjuvant or neoadjuvant therapy to the patient determined to be at high risk for developing or having metastatic breast cancer, wherein the patient was determined to be at high risk for developing or having metastatic breast cancer by determining that the expression level of RKIP was reduced and/or the expression level of one or more of HMGA2, CCL5, TN-FR2, GRN, and CCL7 was elevated in a biological sample from the patient compared to a control non-metastatic tissue sample.
Type:
Application
Filed:
March 11, 2016
Publication date:
April 19, 2018
Inventors:
Marsha Rosner, Casey Frankenberger, Russell Bainer, Daniel Rabe
Abstract: The present disclosure is directed to method of treatment for treating or ameliorating various conditions pertaining such as bone marrow recovery (or blood cell production), fibrosis, inflammatory diseases, inhibition of cancer cell growth, propagation or malignancy, thrombocytopenia, wound healing, and conditions related to stem cells by the administration of BCN057, 512, or an analog thereof.
Abstract: The present invention provides a method of treating squamous histology cancers and PI3K pathway activated large cell lung and colorectal cancers in a patient comprising administering to a patient in need of such treatment an effective amount of 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof; in combination with an effective amount of necitumumab.
Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.
Abstract: The present invention relates to methods of treatment comprising, inter alia, administering a high daily dose of oxycodone, such as a daily dose of at least 90 mg oxycodone, and naloxone in a 2:1 weight ratio to a patient in need thereof.
Type:
Application
Filed:
September 26, 2017
Publication date:
April 19, 2018
Inventors:
Michael HOPP, Petra Leyendecker, Wolfram Kremers
Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
Type:
Application
Filed:
December 18, 2017
Publication date:
April 19, 2018
Inventors:
Michele Hummel, Donald J. Kyle, Garth Whiteside
Abstract: There is provided pharmaceutical compositions for the treatment of rhinitis by, for example, nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutical acceptable aqueous carrier. The compositions are preferably homogeneous in their nature.
Type:
Application
Filed:
April 11, 2012
Publication date:
April 19, 2018
Applicant:
Biolipox AB
Inventors:
Lena Pereswetoff-Morath, Anders Carlsson
Abstract: A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate.
Type:
Application
Filed:
October 3, 2017
Publication date:
April 19, 2018
Applicant:
GALEPHAR PHARMACEUTICAL RESEARCH, INC.
Inventors:
Arthur DEBOECK, Francis Vanderbist, Philippe Baudier, Thami Sebti, Christophe Duret, Karim Amighi
Abstract: A very stable, selective and nrenally safe sodium channel blocker represented by the formula: The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.
Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
Type:
Application
Filed:
December 30, 2015
Publication date:
April 19, 2018
Applicant:
KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
Inventors:
Jong Yeon HWANG, Hyoung Rae KIM, Jae Du HA, Sung Yun CHO, Hee Jung JUNG, Pilho KIM, Chang Soo YUN, Chong Ock LEE, Chi Hoon PARK, Chong Hak CHAE, Sunjoo AHN
Abstract: The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.
Type:
Application
Filed:
June 9, 2017
Publication date:
April 19, 2018
Inventors:
Michael G. Natchus, Richard Arrendale, Dennis Liotta
Abstract: Disclosed are methods of alleviating or preventing one or more symptoms associated with fragile X syndrome in an individual in need thereof via administration of a therapeutically effective amount of a GABA(A) alpha 2 and/or 3 partial agonist. The one or more symptoms may include impaired functional communication, anxiety, inattention, hyperactivity, sensory reactivity, autonomic nervous system dysregulation, aberrant eye gaze, self-injury, aggression, seizures, EEG abnormalities, including but not limited to, abnormal spectral analysis, event related potentials which may include auditory and visual responses, abnormalities in cortical responses as evoked by transcranial magnetic stimulation including resting and active motor thresholds and abnormal responses in measures of cortical inhibition and excitation, aberrant impaired cognitive function, compromised daily living skills, or a combination thereof.
Abstract: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.
Abstract: Described herein are compounds of Formula (I)-(III), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating and/or preventing diseases are also provided.
Type:
Application
Filed:
December 14, 2017
Publication date:
April 19, 2018
Inventors:
Winston Zapanta Ong, Pawel Wojciech Nowak, Ben C. Askew, Jinsoo Kim
Abstract: Compounds of Formula I: wherein: one of X and X? is N and the other of X and X? is C, are described, along with compositions containing the same and methods of use thereof in the treatment of cancer.
Type:
Application
Filed:
October 23, 2017
Publication date:
April 19, 2018
Inventors:
Xiaodong Wang, Jing Liu, Weihe Zhang, Stephen Frye, Dmitri Kireev
Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue. A synergistic composition comprises co-administration of theacrine and caffeine, wherein the co-administered caffeine reduces theacrine oral clearance (CL/F) and oral volume of distribution (Vd/F). In addition, the co-administered caffeine increases area under the plasma concentration time curve (AUC) of theacrine, and increases theacrine maximum plasma concentration (Cmax) in comparison with the corresponding pharmacokinetic parameters when theacrine is administered alone.
Type:
Application
Filed:
May 19, 2017
Publication date:
April 19, 2018
Applicant:
Ortho-Nutra, LLC
Inventors:
Hector L Lopez, Shawn Wells, Tim N. Ziegenfuss
Abstract: The present invention relates to pharmaceutical compositions of linagliptin, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders.
Abstract: Formulations and compositions for the treatment of migraine headaches, and in general, pain, include riboflavin, magnesium, feverfew and an amino acid, such as 5-hydroxytryptophan (5-HTP).
Abstract: Provided are compositions that include a platelet-activating factor antagonist, pharmaceutical compositions including the platelet-activating factor antagonist, methods of treating a modulating the proliferation of a glioma or a pathological condition resulting from patient having a glioma.
Type:
Application
Filed:
March 9, 2016
Publication date:
April 19, 2018
Inventors:
NICOLAS G. BAZAN, ALBERTO E. MUSTO, JULIO ALVAREZ-BUILLA GOMEZ
Abstract: The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
Type:
Application
Filed:
June 28, 2017
Publication date:
April 19, 2018
Inventors:
David C. Griffith, Michael N. Dudley, Mark W. Surber, Keith A. Bostian, Olga Rodny
Abstract: Provided herein are pharmaceutical formulations, nasal irrigation fluids, sachets, kits and the like comprising cephalosporin antibiotics, as well as methods of topical treatment of sinusitis and related conditions, methods of delivery of the formulations and fluids to the sinuses, methods of coating the sinuses, and methods of disruption and/or penetration of biofilms in the sinuses.
Type:
Application
Filed:
October 13, 2017
Publication date:
April 19, 2018
Inventors:
Kambiz YADIDI, Amanda QUIROGA, Jagdeep SHUR, Jeffrey B. Harris
Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating leiomyosarcoma is provided.
Type:
Application
Filed:
April 6, 2016
Publication date:
April 19, 2018
Inventors:
Karim A. Benhadji, Christophe Massard, Jean-Charles Soria
Abstract: The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.
Type:
Application
Filed:
October 23, 2017
Publication date:
April 19, 2018
Applicant:
Topokine Therapeutics, Inc.
Inventors:
Cynthia L. Grosskreutz, Louis R. Pasquale, Michael S. Singer, Murat V. Kalayoglu
Abstract: Dosing regimens for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval are disclosed.
Type:
Application
Filed:
September 14, 2017
Publication date:
April 19, 2018
Applicant:
Agile Therapeutics, Inc.
Inventors:
Thomas M. Rossi, Marie Foegh, Agis Kydonieus
Abstract: Dosing regimens for transdermal delivery of hormones comprising a monthly treatment cycle with a fixed treatment interval and a variable rest interval are disclosed.
Type:
Application
Filed:
September 14, 2017
Publication date:
April 19, 2018
Applicant:
Agile Therapeutics, Inc.
Inventors:
Thomas M. Rossi, Marie Foegh, Agis Kydonieus
Abstract: The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.
Abstract: The present invention relates to a pharmaceutical composition for preventing, treating or delaying an Alzheimer's disease (AD) or dementia including a G protein-coupled receptor19 (GPCR19) agonist or its pharmaceutically acceptable salt as an active ingredient and a food composition for preventing, treating or delaying an Alzheimer's disease or dementia. The GPCR19 agonist according to the present invention has an effect of improving cognitive and behavioral disorders without harming the health of objects when administrated to the objects and has an effect of preventing the Alzheimer's disease or dementia or delaying or treating the progression of the disease in the objects with the disease by suppressing apoptosis of the brain tissue, enhancing immunity, and reducing formation of an amyloid ? (A?) plague.
Type:
Application
Filed:
January 15, 2016
Publication date:
April 19, 2018
Inventors:
Seung Yong SEONG, Jung Ah CHO, Tae Joo KIM, Youn Hee KIM
Abstract: Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general.
Abstract: Butyrylcholinesterase inhibitors, their formulation, and their use primarily in the treatment of neurodegenerative diseases. These inhibitors generally are phosphates, phosphonates, phosphinates, and phosphoramidates. These inhibitors can be incorporated in pharmaceutical compositions and administered to a patient in therapeutically effective amounts to treat neurodegenerative diseases.
Abstract: The present invention relates to a method for preparing a lyophilized composition with improved stability and solubility, which comprises dissolving cyclophosphamide, sodium chloride, and D-mannitol in water as a solvent in a reaction container at 40° C. to 70° C., and a lyophilized cyclophosphamide composition for injection prepared according to the method.
Type:
Application
Filed:
December 20, 2016
Publication date:
April 19, 2018
Inventors:
Won Ho Kang, Won Tae Jung, Young Ho Lee, Jung Hoon Kang, Byuck Ho Kim
Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system.
Abstract: Disclosed is a stable anhydrous dispersion comprising a dispersed sugar phase comprising granulated sugar and powdered sugar, wherein the dispersion comprises 55% to 75% by weight, based on the total weight of the composition, of a combination of granulated sugar and powdered sugar, and a continuous oil phase, wherein the dispersion comprises at least 20% by weight, based on the total weight of the composition, of an oil.
Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
Type:
Application
Filed:
December 15, 2017
Publication date:
April 19, 2018
Applicant:
ABBOTT LABORATORIES
Inventors:
RACHAEL BUCK, GERALYN O. DUSKA-MCEWEN, JOSEPH P. SCHALLER
Abstract: The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a SGLT2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of PDE5 inhibitors or alprostadil.
Type:
Application
Filed:
April 28, 2016
Publication date:
April 19, 2018
Inventors:
Eric Williams MAYOUX, Delphine BEHR-ROUSSEL, Francois GIULIANO
Abstract: The object of the invention is to provide a new composition for suppressing fatty degeneration of a muscle, the composition including a component that is safe and suitable for a long term intake. It was found that quercetin or a glycoside thereof suppresses a differentiation process from myosatellite cells into adipocyte-like cells. In the present invention, quercetin or a glycoside thereof is used in a composition for suppressing fatty degeneration of a muscle.
Type:
Application
Filed:
April 22, 2016
Publication date:
April 19, 2018
Applicant:
SUNTORY HOLDINGS LIMITED
Inventors:
Yuta OTSUKA, Noriyuki KANZAKI, Shuichi MACHIDA